For cervical cancers, pembrolizumab is approved as second line treatment in combination with a platinum-based chemotherapy in patients with PD-L1+ advanced, metastatic or recurrent cervical cancer targeting PD-L1-PD-1-axis [24]. The gene discussed is CD274; the disease is cervical carcinoma.